ecrin-mdr-crcClinical2002Kidney NeoplasmsBreast NeoplasmLung NeoplasmOvarian NeoplasmOvarian NeoplasmsRenal NeoplasmPancreatic NeoplasmsBreast NeoplasmsLung NeoplasmsPancreatic NeoplasmNeoplasmsCancerKidney NeoplasmsBreast NeoplasmLung NeoplasmOvarian NeoplasmOvarian NeoplasmsRenal NeoplasmPancreatic NeoplasmsBreast NeoplasmsLung NeoplasmsPancreatic NeoplasmNeoplasmsCancerInterventionalhttps://newmdr.ecrin.org/Study/2007413United States6Prostate neoplasmGene, HER2Colorectal neoplasmClinical Trial, Phase IECRIN MDRCompletedfalseSafety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2The purpose of this study is to investigate a safe dose of TAK-165, once daily (QD), in patients with HER2-tumor expression.2002-06-152007413NCT00034281U1111-1127-6123